Scientific Program
08:00
Registration
09:00-09:10
Welcome & Opening Remarks
Prof. Dr. Alexander M.M. Eggermont, Netherlands and Prof. Dr. Caroline Robert, France | Congress Chairs
09:10-10:40
Session 1: Prevention & New Screening Technology
09:10-09:35
Primary Prevention: Skin Screening Yes or No?
Susana Puig
Hospital Clínic Barcelona, Spain
09:35-09:40
Discussion/Q&A
09:40-10:05
Advances in Digitalizing Diagnostics From Dermatoscopy to (Whole Body) Photography
Josep Malvehy
Hospital Clínic of Barcelona, Spain
10:05-10:10
Discussion/Q&A
10:10-11:25
Session 2: Risk of Relapse Stratification & Developments in the Surgical Management of Melanoma
10:10-10:20
Short Overview: Reduction Of Surgical Interventions in Melanoma Management
Alexander M.M. Eggermont
Utrecht University, Netherlands
10:20-10:25
Discussion/Q&A
10:25-10:50
Results of the USA Prospective Multicenter Merlin_001 Trial
Tina J. Hieken
Mayo Clinic, Rochester, MN, USA
10:50-10:55
Discussion/Q&A
10:55-11:20
Risk Stratification by Gene Expression Profiling of Primary Melanomas: to which degree can it replace SLNB?
Teresa Amaral
ICANS, Strasbourg, France
11:20-11:25
Discussion/Q&A
11:25-11:45
Coffee Break, Poster Viewing & Visit the Exhibition
11:45-12:15
Session 3: Short Presentations Young Investigators
11:45-11:55
Risk factors for thick melanoma and for melanoma death: implications for screening
11:55-12:05
Cost-effectiveness of an AI-based smartphone app compared to usual care for the early detection of skin cancer in Belgium: A decision tree analysis
12:05-12:15
i31-SLNB for cutaneous melanoma outperforms clinicopathologic-only MIA nomogram at identifying patients at low risk of having positive sentinel lymph node biopsy: A prospective, multicenter study
12:15-12:45
Special Lecture
12:15-12:45
Future Perspectives of Anti-PD1 in CutSCC
Alexander M.M. Eggermont
Utrecht University, Netherlands
12:45-13:45
Lunch Break, Poster Viewing & Visit the Exhibition
13:45-14:30
Session 4: From Adjuvant To Neoadjuvant Strategies
13:45-13:55
Short Update Adjuvant Therapies: Successes and Failures
Alexander M.M. Eggermont
Utrecht University, Netherlands
13:55-14:00
Discussion/Q&A
14:00-14:15
Neoadjuvant Therapies: Where do we go after SWOG1801 and NADINA?
Alexander M.M. Eggermont
Utrecht University, Netherlands
14:15-14:20
Discussion/Q&A
14:20-14:30
Neoadjuvant Revolutions: What can we learn from other tumors?
Alexander M.M. Eggermont
Utrecht University, Netherlands
14:30-15:45
Session 5: What's New in Non Melanoma Skin Cancers
14:30-14:50
CutSCC Carcinoma Overview
Alexander M.M. Eggermont
Utrecht University, Netherlands
14:50-14:55
Discussion/Q&A
14:55-15:15
Merkel Cell Carcinoma
Iwona Ługowska
Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
15:15-15:20
Discussion/Q&A
15:20-15:40
Kaposi Sarcoma
Celeste Lebbé
Saint-Louis Hospital, Paris, France
15:40-15:45
Discussion/Q&A
15:45-16:15
Coffee Break, Poster Viewing & Visit the Exhibition
16:15-16:40
Session 6: What's New In Uveal Melanoma
16:15-16:35
Advanced and Adjuvant
Sophie Piperno-Neumann
Institut Curie, Paris, France
16:35-16:40
Discussion/Q&A
16:40-17:10
Session 7: Management and Outcome of Immune Related Adverse Events
16:40-17:05
Management and Outcome of Immune Related Adverse Events
Karijn Suijkerbuijk
UMC Utrecht Cancer Center, Netherlands
17:05-17:10
Discussion/Q&A
17:10-18:00
Session 8: Short Presentations Young Investigators
17:10-17:20
Cancer Genomics of Basal Cell Carcinoma: Origins and Progression
17:20-17:30
Implication of Alpha-Genus Papillomaviruses in Cutaneous Squamous Cell Carcinoma
17:30
End of Day One
08:30
Registration
09:00-11:30
Session 9: What's New in Advanced Melanoma
09:00-09:20
Role Of Liquid Biopsies in Decision Making in Adjuvant and Advanced Melanoma Setting
Christoffer Gebhardt
University Medical Center Hamburg-Eppendorf (UKE), Germany
09:20-09:25
Discussion/Q&A
09:25-09:45
Emerging Role of ctDNA in Melanoma Management
Paul Lorigan
The Christie NHS Foundation Trust, UK
09:45-09:50
Discussion/Q&A
09:50-10:10
Biomarkers And Decision-Making Monotherapy Or Combination Therapies/Schedules In Advanced Melanoma: Conclusions Of Dreamseq-Secombit And Ebin Trials
Caroline Robert
Gustave Roussy Cancer Campus, Paris, France
10:10-10:15
Discussion/Q&A
10:15-10:35
What's New in Advanced Melanoma 1st Line - NEW DOUBLETS and TRIPLETs ICI
Mario Mandalà
University of Perugia, Santa Maria Misericordia Perugia, Italy
10:35-10:40
Discussion/Q&A
10:40-11:00
What's New in Advanced Melanoma 1st Line - TME-modulating VACCINE
Jessica C. Hassel
University Hospital Heidelberg, Germany
11:00-11:05
Discussion/Q&A
11:05-11:25
What's New in Advanced Melanoma 1st Line - Various Vaccines, New Agents
Olivier Michielin
University Hospital Geneva, Switzerland
11:25-11:30
Discussion/Q&A
11:30-12:00
Coffee Break, Poster Viewing & Visit the Exhibition
12:00-13:15
Session 10: Short Presentations Young Investigators
12:00-12:10
Intralesional Interleukin-2 Therapy is Highly Effective in Treatment of Cutaneous Squamous Cell Carcinoma
12:10-12:20
Early cessation of adjuvant anti-PD-1 therapy in stage III and IV melanom
12:20-12:30
RECQL4 Overexpression Fosters Immune Escape and Anti-PD-1 Resistance in Melanoma
12:30-12:40
The 31-Gene Expression Profile is an Independent Predictor of Poor 5-Year Outcomes and Identifies High-Risk Cutaneous Melanoma in Patients with a Negative Sentinel Lymph Node
12:40-12:50
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin
12:50-13:00
Clinical Outcomes and Toxicity of Combined Ipilimumab and Nivolumab in Rare Melanomas – a Nationwide Population-Based Study
13:00-13:10
Outcomes of patients with T1a primary melanoma close to critical anatomic structures treated with narrower excision of 5 mm instead of 10 mm
13:10-13:15
Discussion
13:15-14:15
Lunch Break, Poster Viewing & Visit the Exhibition
14:15-15:30
Session 11: What's New in Melanoma 2nd Line: PD-1 Refractory Advanced Melanoma 2nd Line
14:15-14:35
Oncolytic Vaccines
Caroline Robert
Gustave Roussy Cancer Campus, Paris, France
14:35-14:40
Discussion/Q&A
14:40-15:00
TIL Therapy
Inge Marie Svane
Copenhagen University Hospital, Herlev, Denmark
15:00-15:05
Discussion/Q&A
15:05-15:30
PANEL DISCUSSION 1st and 2nd Line What's New?
Alexander M.M. Eggermont
Utrecht University, Netherlands
Caroline Robert
Gustave Roussy Cancer Campus, Paris, France
Inge Marie Svane
Copenhagen University Hospital, Herlev, Denmark
15:30-16:00
Poster Award Ceremony, Closing Remarks & End of Congress
Prof. Dr. Alexander M.M. Eggermont, Netherlands and Prof. Dr. Caroline Robert, France | Congress Chairs
16:00
Farewell Coffee Break & Networking